Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-05-12 AGM Information
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于安徽峆一药业股份有限公司2023年年度股东大会的法律意见书
AGM Information Classification · 80% confidence The document is a formal legal opinion (“法律意见书”) issued by the company’s lawyers regarding the convening, procedures, attendance qualifications, agenda and voting results of the 2023 Annual General Meeting. It is not a full annual or interim financial report, nor just a simple voting results announcement—it is part of the AGM materials provided to shareholders. Therefore it best fits the AGM Information category (AGM-R).
2024-05-12 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2023 Annual General Meeting (AGM) resolution announcement for Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on various proposals including the 2023 annual report, audit report, financial budget, and other corporate matters. The document does not contain the full annual report or financial statements but rather the resolutions passed at the AGM. It references other documents published on the stock exchange website but does not include those reports themselves. The content is consistent with an official announcement of voting results and resolutions from the AGM, not the report or financial data itself. Therefore, the correct classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6247 characters) and detailed voting results support this classification with high confidence.
2024-05-12 Chinese
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a performance explanation meeting (业绩说明会) held on May 7, 2024, where company executives answered investor questions about business operations, future plans, and market conditions. The document is short (1225 characters) and consists mainly of Q&A from an investor relations event rather than a formal financial report or earnings release. It does not contain actual financial statements or substantive financial data. This matches the description of an Investor Presentation (IP) as it focuses on financials, strategy, and market position communicated to investors in a meeting format. Therefore, the appropriate classification is Investor Presentation (IP).
2024-05-08 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Anhui Xuyi Pharmaceutical Co., Ltd. regarding the receipt of an invention patent certificate. It includes details about the patent, its application date, authorization date, and the impact on the company. There is no financial data, no mention of financial results, no regulatory filings, or meeting materials. It is a regulatory announcement about intellectual property rights, which does not fit into financial report categories. Given the nature and length of the document, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-05-08 Chinese
2023 年年度报告说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled annual report earnings explanation meeting (业绩说明会) for the 2023 annual report. It references the 2023 annual report that was already disclosed on April 11, 2024, and invites investors to participate in a webcast meeting on May 7, 2024. The document does not contain the annual report itself or detailed financial data, but rather announces the upcoming investor presentation related to the annual report. The document length is short (1021 characters) and it is clearly an announcement of a meeting to discuss the annual report, not the report itself. Therefore, it fits the category of Investor Presentation (IP).
2024-04-28 Chinese
关于拟注销子公司的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the decision by the company's board of directors to dissolve a subsidiary company. It includes details about the subsidiary, the board meeting resolution, and the rationale behind the decision. There is no financial data, audit information, or report attached. The content focuses on a board decision and management action. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company structure or management decisions.
2024-04-25 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.